Health care stocks were mixed premarket Tuesday with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) recently up 0.1%.
Arvinas (ARVN) and Pfizer (PFE) said a phase 3 clinical trial of vepdegestrant monotherapy as an investigational treatment for advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but did not reach statistical significance in progression-free survival improvement in the intent-to-treat population. Arvinas shares fell by more than 37% pre-bell.
Legend Biotech (LEGN) shares were up more than 1% after the company reported a narrowed Q4 adjusted net loss as revenue increased during the period.
Illumina (ILMN) shares rose past 2% after the company announced a $100 million cost reduction program, while lowering its fiscal 2025 non-GAAP earnings forecast.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.